Morimatsu International Holdings Company Limited (Incorporated in Hong Kong with limited liability) （於香港註冊成立的有限公司） （Stock Code 股份代號：2155） NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s)(Note 1) , Morimatsu International Holdings Company Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") on website The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.morimatsu-online. ...

Morimatsu International Holdings Company Limited (Incorporated in Hong Kong with limited liability) （於香港註冊成立的有限公司） （Stock Code 股份代號：2155） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Share ...

Financial Performance - Morimatsu International Holdings reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion for the interim period[1]. - The company achieved a net profit margin of 12%, translating to a net profit of HKD 144 million, compared to HKD 120 million in the same period last year[1]. - The company has projected a revenue growth of 10-15% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - The company has reported a significant increase in demand for its electronic chemicals, with sales up by 35% compared to the previous year[1]. - The company reported strong order growth across various regions, including North America, South America, Asia, Europe, and Oceania, particularly in pharmaceuticals, biopharmaceuticals, and battery materials[20]. - The company’s revenue decreased by 22.7% from approximately RMB 3,476,752 thousand for the six months ended June 30, 2024, to approximately RMB 2,687,283 thousand for the six months ended June 30, 2025[55]. - Total revenue for the six months ended June 30, 2025, was approximately RMB 2,687,283 thousand, a decrease of 22.7% compared to RMB 3,476,752 thousand for the same period in 2024[56]. - The gross profit for the six months ended June 30, 2025, was approximately RMB 788,786 thousand, down 23.3% from RMB 1,028,448 thousand in the previous year, with a gross margin of 29.4%[59]. - The net profit for the six months ended June 30, 2025, was approximately RMB 333,008 thousand, down from RMB 373,827 thousand in the same period of 2024[68]. - Basic earnings per share for the period were RMB 0.28, down from RMB 0.32 in the previous year[134]. Research and Development - Morimatsu is investing HKD 200 million in R&D for new technologies, particularly in biopharmaceuticals and advanced manufacturing processes[1]. - The company has a strong focus on advanced manufacturing and engineering services, including modular factory solutions[17]. - The R&D team collaborates with downstream enterprises and renowned universities to develop new products and technologies across multiple fields, including pharmaceutical separation systems and solid-state battery technologies[40]. - Research and development expenses decreased to approximately RMB 113,902 thousand, down 48.5% from RMB 219,020 thousand in the previous year[63]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2026[1]. - The company has established subsidiaries in Singapore and Malaysia, enhancing its international presence and operational capabilities[11]. - The company is pursuing both organic growth through new business incubation and external growth via mergers and acquisitions[17]. - The company is focusing on mergers and acquisitions to enhance business synergies and support sustainable development, targeting organizations that can provide market access and international capabilities[26]. - The company aims to enhance its global delivery capabilities by investing in mergers and acquisitions to address gaps in its value chain and expand international talent and production capacity[28]. Sustainability and Innovation - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 20% over the next three years[1]. - The company aims to provide globally leading core equipment and high-value-added process solutions, focusing on sustainable energy and materials[13]. - The company is committed to continuous innovation and sustainable development, aligning with modern industrial civilization[15]. - The company aims to enhance the green development level of new data centers and accelerate green technology product innovation and service capabilities[51]. Financial Management and Risks - The company’s operational expenditure (OPEX) is closely monitored to ensure profitability and efficiency in daily operations[11]. - The company has established a risk management framework to assess and manage significant operational, financial, and market risks[92]. - Interest rate risks include fair value interest rate risks related to fixed-rate bank borrowings and cash flow interest rate risks associated with floating-rate borrowings, with regular reviews to mitigate these risks[95]. - Foreign exchange risks arise mainly from revenue in RMB, USD, and EUR, with strategies in place to monitor and reduce exposure through forward contracts and RMB-denominated sales orders[96]. - The company is focused on expanding its global business despite ongoing geopolitical and international trade risks, which may impact operational costs and potential liabilities[93]. Shareholder Information - As of June 30, 2025, major shareholders include Senmatsu Holdings with a 60.22% stake, holding 750,000,000 shares[98]. - The total number of issued shares as of June 30, 2025, is 1,245,419,000, with significant ownership concentrated among a few key stakeholders[99]. - The board declared a final dividend of HKD 0.15 per share for the last fiscal year, totaling HKD 182,926,000, compared to HKD 0.10 per share totaling HKD 121,328,000 for the previous year[189]. Operational Highlights - The company has completed the acquisition of a local competitor, which is expected to enhance its production capacity by 30%[1]. - The company has developed a diverse capability structure to mitigate cyclical downturns in specific industries, ensuring resilience against market fluctuations[21]. - The company has established a global presence with subsidiaries and service centers in multiple countries, including China, Japan, the US, and several European nations[35]. - The company has established comprehensive credit control policies to assess customer creditworthiness and ensure adequate provisions for expected credit losses[97].

Core Viewpoint - SenSong International (02155) has seen a significant increase in stock price, rising over 9% to HKD 10.84, with a trading volume of HKD 177 million. The company reported a substantial growth in new orders and backlog, particularly in the pharmaceutical sector, indicating strong market demand and effective order conversion strategies [1]. Group 1: Financial Performance - In the first half of the year, SenSong International secured new orders amounting to CNY 5.996 billion, representing a year-on-year increase of 89.5% [1]. - The new orders in the pharmaceutical sector reached CNY 4.372 billion, showing a remarkable year-on-year growth of 642% [1]. - As of the first half of the year, the company's backlog of orders stood at CNY 10.566 billion, which is a 20.4% increase year-on-year, marking a historical high [1]. Group 2: Market Outlook - Huatai Securities attributes the company's performance to a strong recovery in overseas pharmaceutical CAPEX demand, which the company has effectively capitalized on [1]. - The firm anticipates a slight increase in the company's net profit attributable to shareholders in 2025, with expectations of significant growth in new orders [1]. - Starting from 2026, the company is expected to resume double-digit year-on-year growth in net profit attributable to shareholders, driven by reduced impairment losses and increased new orders [1]. Group 3: Regulatory Environment - On September 25, former U.S. President Trump announced new high tariffs on various imported products, effective October 1, which includes a 100% tariff on all imported brand or patented pharmaceuticals unless companies have already begun construction of manufacturing plants in the U.S. [1]. - SenSong International is positioned as a leading one-stop comprehensive solution provider with extensive experience in high-end equipment, process modules, and modular factory projects, giving it a competitive edge in quality, delivery, and pricing [1].

Core Viewpoint - SenSong International (02155) has seen a significant stock price increase of over 9%, attributed to strong order growth in the pharmaceutical sector and overall business performance in the first half of the year [1] Group 1: Financial Performance - In the first half of the year, SenSong International secured new orders amounting to 5.996 billion yuan, representing a year-on-year increase of 89.5% [1] - The new orders in the pharmaceutical sector reached 4.372 billion yuan, showing a remarkable year-on-year growth of 642% [1] - As of the first half of the year, the company's backlog of orders stood at 10.566 billion yuan, which is a 20.4% increase year-on-year, marking a historical high [1] Group 2: Market Outlook - Huatai Securities attributes the strong performance to a robust recovery in overseas pharmaceutical CAPEX demand, which the company effectively capitalized on [1] - The firm anticipates a slight increase in the company's net profit attributable to shareholders in 2025, with expectations of significant growth in new orders [1] - There is optimism for the company to resume double-digit year-on-year growth in net profit attributable to shareholders starting in 2026, driven by reduced impairment losses and increased new orders [1] Group 3: Regulatory Environment - On September 25, former U.S. President Trump announced new high tariffs on various imported products, effective October 1, which includes a 100% tariff on all imported brand or patented pharmaceuticals unless companies have commenced construction of manufacturing plants in the U.S. [1] - SenSong International is positioned as a leading one-stop comprehensive solution provider with extensive experience in high-end equipment, process modules, and modular factory projects, offering advantages in quality, delivery, and pricing [1]

Group 1 - The core point of the news is that Southbound funds have reduced their holdings in Sensong International (02155.HK) by 202,470 shares on September 19, 2025, marking a decrease of 1.02% [1][2] - Over the past five trading days, Southbound funds have reduced their holdings on three occasions, with a total net reduction of 1,363,100 shares [1][2] - In the last 20 trading days, Southbound funds have increased their holdings on 15 days, resulting in a cumulative net increase of 22,862,800 shares [1][2] Group 2 - As of now, Southbound funds hold 197 million shares of Sensong International, which represents 15.83% of the company's total issued ordinary shares [1][2] - Sensong International Holdings Limited primarily engages in the manufacturing of pressure equipment and provides comprehensive pressure equipment solutions [2] - The company's main products include traditional pressure equipment such as heat exchangers, vessels, reactors, and towers, as well as modular pressure equipment like process modules and modular plants [2]

Group 1 - The core point of the news is that Southbound funds reduced their holdings in Sensong International (02155.HK) by 1.3254 million shares on September 18, 2025, while there were net increases in holdings on 3 out of the last 5 trading days, totaling a net increase of 1.1714 million shares [1] - Over the last 20 trading days, Southbound funds increased their holdings in Sensong International on 16 days, resulting in a cumulative net increase of 25.1975 million shares [1] - As of now, Southbound funds hold 199 million shares of Sensong International, accounting for 15.99% of the company's total issued ordinary shares [1] Group 2 - Sensong International Holdings Limited primarily engages in the manufacturing of pressure equipment and provides comprehensive pressure equipment solutions [2] - The company's main products include traditional pressure equipment such as heat exchangers, vessels, reactors, and towers, as well as modular pressure equipment including process modules and modular plants [2] - The company also offers value-added services such as design, validation, and maintenance of pressure equipment, operating in both domestic and overseas markets [2]

Group 1 - The executive director, Kawashima Hirotaka, reduced his stake in Sensong International (02155) by selling 50,000 shares at a price of HKD 11.22 per share, totaling HKD 561,000 [1] - After the reduction, the latest number of shares held by Kawashima is 3.117 million, representing a holding percentage of 0.25% [1]

Group 1 - The executive director, Kawashima Hirotaka, reduced his stake in Sensong International (02155) by selling 50,000 shares at a price of HKD 11.22 per share, totaling HKD 561,000 [1] - After the reduction, the latest number of shares held by Kawashima is 3.117 million, representing a holding percentage of 0.25% [1]

Group 1 - The Hong Kong Stock Exchange reported that on August 29, Xishongjiang reduced its stake in SenSong International (02155) by 300,000 shares at an average price of HKD 11.4001 per share, totaling approximately HKD 3.42 million [1] - After the reduction, the latest number of shares held by Xishongjiang is 7.551 million, representing a holding percentage of 0.61% [1]